Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H21NO3 |
| Molecular Weight | 347.407 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1
InChI
InChIKey=DGENZVKCTGIDRZ-UHFFFAOYSA-N
InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24758921 | https://www.ncbi.nlm.nih.gov/pubmed/21593768 | https://www.ncbi.nlm.nih.gov/pubmed/24349089 | https://www.ncbi.nlm.nih.gov/pubmed/23341496
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24758921 | https://www.ncbi.nlm.nih.gov/pubmed/21593768 | https://www.ncbi.nlm.nih.gov/pubmed/24349089 | https://www.ncbi.nlm.nih.gov/pubmed/23341496
GW-9508 is a small-molecule agonist of the fatty acid receptors GPR40 and GPR120. GW-9508 exerts wide-range activity in animal models: anti-depressant, anti-inflammatory, anti-diabetic and analgetic actions.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24758921 | https://www.ncbi.nlm.nih.gov/pubmed/24349089
Curator's Comment: GW9508 is CNS active in animals. No human data available.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4422 |
7.32 null [pEC50] | ||
Target ID: CHEMBL5339 |
5.46 null [pEC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. | 2007 Apr |
|
| Free fatty acid receptors and drug discovery. | 2008 Oct |
|
| Involvement of the long-chain fatty acid receptor GPR40 in depression-related behavior. | 2014 |
Patents
Sample Use Guides
mice: 30-100 uM GW9508 topically to the skin in the challenging phase suppressed ear swelling in a repeated hapten application model and contact hypersensitivity with downregulation of CCL5 and CXCL10, respectively.
mice: 50 mg/kg ip GW-9508 enhanced glucose-induced plasma insulin levels significantly and thus decreased glucose injection-induced hyperglycemia.
mice: 1 ug icv GW-9508 for 5 days may regulate depression-related behavior.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
885101-89-3
Created by
admin on Sat Dec 16 10:44:08 GMT 2023 , Edited by admin on Sat Dec 16 10:44:08 GMT 2023
|
PRIMARY | |||
|
4T77GYP2CS
Created by
admin on Sat Dec 16 10:44:08 GMT 2023 , Edited by admin on Sat Dec 16 10:44:08 GMT 2023
|
PRIMARY | |||
|
DTXSID70237088
Created by
admin on Sat Dec 16 10:44:08 GMT 2023 , Edited by admin on Sat Dec 16 10:44:08 GMT 2023
|
PRIMARY | |||
|
11595431
Created by
admin on Sat Dec 16 10:44:08 GMT 2023 , Edited by admin on Sat Dec 16 10:44:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
